Key result
Latent profile analysis identified three distinct idiopathic short stature phenotypes, revealing that older poor responders had the least improvement in height standard deviation score despite receiving the highest growth hormone dose.
Why the study?
Idiopathic short stature is heterogeneous and responsiveness to growth hormone treatment varies, necessitating identification of homogeneous phenotypes to better assess treatment response before initiation.
Does latent profile analysis identify distinct phenotypes that predict response to growth hormone treatment in children with idiopathic short stature?
Cohort (n=218)
Yes
Does latent profile analysis identify distinct phenotypes that predict response to growth hormone treatment in children with idiopathic short stature?
Latent profile analysis identifies distinct phenotypes in children with idiopathic short stature, enabling personalized prediction of growth hormone treatment response based on pretreatment height velocity and peak growth hormone levels.
Answers are grounded in this paper and cite their sources.
May identify high-dose, low-response subgroups in idiopathic short stature; leaves open prospective validation of phenotype-guided therapy.
Idiopathic short stature (ISS) is a heterogeneous group and their responsiveness to growth hormone treatment varies among individuals. The aim of this study was to identify homogeneous phenotypes to better assess response before the initiation of treatment. We focused on person-centered approaches using a latent profile analysis. Clinical data of 218 children (127 boys and 91 girls) aged 4-15 years were obtained from the "LG Growth Study" which is a non-interventional Korean multicenter registry for growth hormone treatment. Growth hormone dose, first-year difference in height standard deviation score (Δheight SDS), mid-parental height SDS, and initial bone age were inputted into the model. The distribution of scatter plot was clearly distinguished at the chronological age of 8.83 years, Δheight SDS of 0.82 and mean GH dose of 0.36 mg/kg/week. The latent profile analysis revealed three distinct phenotypes names as follows: younger good responder (n = 56), older good responder (n = 111), and older poor responder (n = 51) groups. Despite more than twice the mean growth hormone dose, the older poor responder group showed the least improvement in the mean Δheight SDS. The pretreatment height velocity and peak growth hormone level were lower for the older poor responder group compared with those of the older good responder group. The statistically optimal cutoff point for predicting poor response was 3.41 cm/year for pretreatment height velocity and 9.18 ng/mL for peak growth hormone level. This study offers a new multidimensional approach to enable personalized growth hormone treatment optimization according to ISS phenotypes.
No takes yet. Share an insight, caveat, or question.
Nam et al. (2019) conducted a cohort in Idiopathic Short Stature (n=218). Growth hormone treatment was evaluated on First-year difference in height standard deviation score (Δheight SDS) (p=<0.001). Latent profile analysis identified three distinct idiopathic short stature phenotypes, revealing that older poor responders had the least improvement in height standard deviation score despite receiving the highest growth hormone dose.
Synapse has enriched 10 related papers. Consider them for comparative context: